Aulbert E, Jakob M, Kurschel E
Ev. Waldkrankenhaus Spandau, Akad. Lehrkrankenhaus der FU Berlin, Berlin-Spandau.
Onkologie. 1989 Apr;12(2):81-9. doi: 10.1159/000216606.
Transferrin is a growth factor in malignancy. In this function, transferrin is taken up into the proliferating malignant cell. The tumor-induced loss of circulating transferrin results in a hypotransferrinemia which correlates with tumor mass and proliferation rate. The cellular uptake of iron into the erythropoietic precursors depends on the presence of iron-saturated transferrin. Thus, iron utilization for the hemoglobin synthesis correlates with the transferrin concentration in blood. In 256 patients with malignancies of different histological types and different tumor extension a strong correlation was found between the degree of tumor-induced hypotransferrinemia and anemia. This correlation between transferrin concentration and hemoglobin concentration could be demonstrated in the different histological tumor entities. Tumor progression was accompanied by a progressive fall in transferrin concentration and hemoglobin concentration. By contrast, tumor remission achieved by an effective antineoplastic therapy resulted in an improvement of hypotransferrinemia and anemia. These variations in the two parameters were found to be strongly correlated. We conclude from our data that tumor-induced loss of transferrin is one of the most important factors responsible for the development of anemia in malignancy.
转铁蛋白是恶性肿瘤中的一种生长因子。在此功能中,转铁蛋白被增殖的恶性细胞摄取。肿瘤导致循环转铁蛋白减少,引起低转铁蛋白血症,这与肿瘤大小和增殖速率相关。红细胞生成前体细胞对铁的细胞摄取取决于铁饱和转铁蛋白的存在。因此,用于血红蛋白合成的铁利用与血液中转铁蛋白浓度相关。在256例不同组织学类型和不同肿瘤分期的恶性肿瘤患者中,发现肿瘤诱导的低转铁蛋白血症程度与贫血之间存在强烈相关性。转铁蛋白浓度与血红蛋白浓度之间的这种相关性在不同组织学肿瘤实体中均可得到证实。肿瘤进展伴随着转铁蛋白浓度和血红蛋白浓度的逐渐下降。相比之下,有效的抗肿瘤治疗实现的肿瘤缓解导致低转铁蛋白血症和贫血得到改善。发现这两个参数的这些变化密切相关。我们从数据中得出结论,肿瘤诱导的转铁蛋白丢失是恶性肿瘤中贫血发生的最重要因素之一。